Is letrozole more effective in increasing pregnancy rates than clomiphene citrate in infertile women with polycystic ovary syndrome?

2019 ◽  
Vol 22 (6) ◽  
pp. 24-25
Author(s):  
Richard Sundermeyer ◽  
Claire Thomas ◽  
Wyman Gilmore ◽  
Trevor Johnson ◽  
Assiatu Bah
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Pregnancy Rates ◽  
Ovary Syndrome ◽  
Infertile Women

scholarly journals Comparision of Rosiglitazone Maleat Only Use with Combination with Clomiphene Citrate in Infertile Cases with Clomiphen Resistant Polycystic Ovary Syndrome Cases

2021 ◽  
Author(s):  
Sevinç Ünal ◽  
Memet Şimşek
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Statistical Significance ◽  
Clomiphene Citrate ◽  
Pregnancy Rates ◽  
Induction Agent ◽  
Ovary Syndrome ◽  
Insulin Sensitizer ◽  
Group 2 ◽  
Group 1

INTRODUCTION: Most of the obese PCOS patients are resistant to clomiphene citrate standard doses. In these cases metabolic syndromes are treated by using insulin sensitizing drugs so that ovulation can be achieved.In this study rosiglitazine maleat was used in order to induce ovulation in obese clomiphene resistant PCOS patients. METHODS: 30 women(18-40 year old) with clomiphene resistant polycystic ovary syndrome that were obese (BMI>25 kg/m2) and hyperinsulinemic were seperated in two groups. In the first group (n=15) oral antidiabetic Rosiglitazone maleate( 4mg bid) which belongs to thiazolidinediones were used.In the second group(n=15) in addition to clomiphen citrate(50 bid)and Rosiglitazone maleate(4 mg bid) were used, ovulation and pregnancy rates were compared. In both groups ovulation and pregnancy were recorded, in the second group ovulation and pregnancy rates were higher than the first group but these rates were not significant. RESULTS: In group 1, ovulation was achieved in 5 patients (%33) and pregnancy was achieved in 1 patient (%7). In group 2, ovulation was achieved in 9 patients (%60) and pregnancy was achieved in 3 patients (%20).There was no statistical significance between two groups. DISCUSSION AND CONCLUSION: In our study in obese and hyperinsulinemic patients rosiglitazone maleat can induce ovulation and in addition to clomiphene citrate also ovulation can be achieved although it is statistical insignificant. As a result Rosiglitazone maleate can be used alternatively as an insulin sensitizer and ovulation induction agent.

scholarly journals Use of letrozole versus clomiphene citrate combined with gonadotropins for ovulation induction in infertile women with polycystic ovary syndrome: a pilot study

2017 ◽  
Vol 6 (9) ◽  
pp. 4098 ◽  
Author(s):  
Amitoj Athwal ◽  
Ratnabali Chakravorty ◽  
Dipanshu Sur ◽  
Rupam Saha
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Prospective Trial ◽  
Serum Estradiol ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Ovulation Stimulation ◽  
Group Serum

Background: The aim of the study was to evaluate the efficacy of letrozole and clomiphene citrate (CC) in gonadotropin-combined for ovulation stimulation in women with polycystic ovary syndrome (PCOS). It was a prospective pilot study.Methods: This prospective trial included 124 patients of infertile women with PCOS. Letrozole dose of 5 mg/day (n = 65) or a CC dose of 100 mg/day (n = 59) was given on day 3 to day 7 of the menstrual cycle, combined with gonadotropin i.e. follicle stimulating hormone (FSH) at a dose 75 IU every day starting on day 7 and continued to day 9. Main outcome measures were occurrence of ovulation, number of mature follicles, serum estradiol (E2) and endometrial thicknesses on the day of human chorionic gonadotropin (hCG), and pregnancy rates.Results: The clinical profile including mean age, duration of infertility, BMI, baseline FSH, LH and E2 of patients belonging to both groups were comparable. The numbers of mature follicles (4.3±0.3 vs. 2.9±0.7) were significantly higher in letrozole+FSH group. Serum E2 levels on the day of hCG (301.78±85.7 vs. 464.7±72.9 pg/mL) were significantly lower in the letrozole+FSH group. Significant differences were found in endometrial thickness measured on the day of hCG in letrozole+FSH group (p=<0.0001). The rate of ovulation was higher in letrozole+FSH group and it was marginally statistically significant (p=0.040). The rate of pregnancy was slightly greater in the letrozole+FSH group (17.85% versus 13.33%), although not statistically significant.Conclusions: Letrozole in combination with FSH appears to be a suitable ovulation inducing agent versus CC with FSH in PCOS. This combination may be more appropriate in patients who are particularly sensitive to gonadotropin.

scholarly journals PRESCRIPTION PATTERN IN OBESE AND NON-OBESE INFERTILE WOMEN WITH POLYCYSTIC OVARY SYNDROME IN A TERTIARY CARE HOSPITAL

2018 ◽  
Vol 11 (3) ◽  
pp. 53
Author(s):  
Asha Avirah Mm ◽  
Aswathy Alias ◽  
Manjusha Sajith ◽  
Vandana Nimbargi ◽  
Shivhar Kumdale
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Treatment Options ◽  
Tertiary Care ◽  
Care Hospital ◽  
Lifestyle Modifications ◽  
Ovary Syndrome ◽  
Infertile Women ◽  
Current Medication

 Objective: The objective of this study is to evaluate the treatment options for the management of obese and non-obese infertile women with polycystic ovary syndrome (PCOS).Methods: A prospective observational study was conducted with 75 infertile PCOS women. The demographic details, body mass index, menstrual patterns, and current medication related to infertility were noted. The collected data were statistically represented in terms of range, frequency tables, and standard deviation wherever appropriate.Results: A majority of the infertile PCOS women were aged 24–27 years with a mean age of 25.72±3.53 years, belonging to middle socioeconomic class (44%) and mostly found to be urban residents 68%. Most of the PCOS women were overweight (32%) and obese (21%) with irregular menstrual pattern (90.67%). In combination therapy, clomiphene citrate (CC) pre-treated with oral contraceptives (OC) (37.93%) was mostly given to obese PCOS patients followed by CC with metformin pre-administered with OC (31.03%), whilen on-obese PCOS patients were mostly administered CC with gonadotropins pre-treated with OC(44%). In single therapy, OC was mostly administered to both non-obese (90%) and obese PCOS patients (88.90%).Conclusion: This study concluded that most of the infertile PCOS women were overweight and obese, a major risk actor causing hyperandrogenicity. CC pre-treated with OC and metformin with CC pre-treated with OC were mostly prescribed to obese PCOS patients. Lifestyle modifications along with treatment are strongly recommended, especially in obese PCOS patients.

Sign in / Sign up

Export Citation Format

Share Document